Search

Your search keyword '"Pellicelli, Adriano M"' showing total 149 results
Start Over Author "Pellicelli, Adriano M"
149 results on '"Pellicelli, Adriano M"'

3. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection

Author

Fontana, Robert J., Brown, Robert S., Jr, Moreno-Zamora, Ana, Prieto, Martin, Joshi, Shobha, Londoño, Maria-Carlota, Herzer, Kerstin, Chacko, Kristina R., Stauber, Rudolf E., Knop, Viola, Jafri, Syed-Mohammed, Castells, Lluís, Ferenci, Peter, Torti, Carlo, Durand, Christine M., Loiacono, Laura, Lionetti, Raffaella, Bahirwani, Ranjeeta, Weiland, Ola, Mubarak, Abdullah, ElSharkawy, Ahmed M., Stadler, Bernhard, Montalbano, Marzia, Berg, Christoph, Pellicelli, Adriano M., Stenmark, Stephan, Vekeman, Francis, Ionescu-Ittu, Raluca, Emond, Bruno, and Reddy, Rajender K.

Published
2016
Full Text
View/download PDF

5. Benefit of weight based dosages of Ribavirin (RBV) in combination with PegInterferon (PegIFN) α2a in naïve patients with HCV2 and HCV3: results of an Italian Randomized Controlled Trial, the WRITE study: 1737

Author

Mangia, Alessandra, Francavilla, Ruggiero, Merola, Velia, Barbarini, Giorgio -., Russello, Maurizio, Nosotti, Lorenzo, Minerva, Nicola, Bacca, Donato, Romano, Mario, Cuccorese, Giuseppe, Montalto, Giuseppe, Agostinacchio, Ernesto, De Luna, Antonio, Mariano, Corrado, Monti, Monica, Pellicelli, Adriano M., Sogari, Fernando, Mottola, Leonardo, Petruzzellis, Daniela, Piazzolla, Valeria, Ripoli, Maria, Santoro, Rosanna, and Mecenate, Fabrizio

Published
2012

6. Impact of liver fibrosis in development of hepatocellular carcinoma in HBeAg negative genotype D patients with chronic hepatitis B treated with nucleos(†)ide analogues: 21

Author

Pellicelli, Adriano M., Vignally, Pascal, Mazzoni, Ettore, Izzi, Antonio, Mecenate, Fabrizio, Romano, Mario, Barlattani, Angelo, Villani, Roberto, Guarascio, Paolo, Furlan, Caterina, Cerasari, Giuseppe, Bacca, Donato, DʼAmbrosio, Cecilia, Fondacaro, Lucia, Miglioresi, Lucia, Bonaventura, Maria Elena, Andreoli, Arnaldo, and Barbarini, Giorgio

Published
2012

7. Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Author

Sacco, Rodolfo, primary, Messina, Vincenzo, additional, Vespasiani Gentilucci, Umberto, additional, Adinolfi, Luigi Elio, additional, Ascione, Antonio, additional, Barbarini, Giorgio, additional, Barlattani, Angelo, additional, Cariti, Giuseppe, additional, Cozzolongo, Raffaele, additional, Fimiani, Basilio, additional, Francavilla, Ruggiero, additional, Furlan, Caterina, additional, Garrucciu, Giovanni, additional, Iovinella, Vincenzo, additional, Rinaldi, Luca, additional, Marignani, Massimo, additional, Begini, Paola, additional, Palitti, Valeria Pace, additional, Pellicelli, Adriano M, additional, Scifo, Gaetano, additional, Facciorusso, Antonio, additional, Giacomelli, Luca, additional, Shah, Aashni, additional, Bertino, Gaetano, additional, Perazzo, Serena, additional, Bresci, Giampaolo, additional, and Izzi, Antonio, additional

Published
2020
Full Text
View/download PDF

9. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon α-2a and ribavirin: a multicentric study

Author

Puoti, Claudio, Pellicelli, Adriano M., Romano, Mario, Mecenate, Fabrizio, Guarisco, Riccardo, Barbarini, Giorgio, Mazzoni, Ettore, Spilabotti, Lucia, Bellis, Lia, Paglia, Federica, Barlattani, Angelo, Picardi, Antonio, Paffetti, Amerigo, Bonaventura, Maria Elena, Nosotti, Lorenzo, Mitidieri, Olga, Dellʼ Unto, Orlando, Villani, Roberto, Dellʼ Unto, Chiara, Morrone, Aldo, and Soccorsi, Fabrizio

Published
2009
Full Text
View/download PDF

11. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

Author

Di Maio, Velia C., Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F., Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C., Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M., Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio Maria, Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxì, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F., Ceccherini Silberstein, Francesca, Mariani, R., Iapadre, N., Grimaldi, A., Cozzolongo, R., Andreone, P., Verucchi, G., Menzaghi, B., Quirino, T., Pisani, V., Torti, MARIA CHIARA, Vecchiet, J., Bruzzone, B., De Maria, A., Marenco, S., Nicolini, L. A., Viscoli, C., Casinelli, K., Delle Monache, M., Lichtner, Miriam, Aghemo, A., Boccaccio, V., Bruno, S., Cerrone, M., Colombo, M., D'Arminio Monforte, A., Danieli, E., Donato, F., Gubertini, G., Lleo, A., Magni, C. F., Mancon, A., Monico, S., Niero, F., Russo, M. L., Gnocchi, M., Orro, A., Milanesi, L., Baldelli, E., Bertolotti, M., Borghi, V., Mussini, C., Brancaccio, G., Gaeta, G. B., Lembo, V., Sangiovanni, V., Di Marco, V., Mazzola, A., Petta, S., D'Amico, E., Cacciatore, P., Consorte, A., Pieri, A., Polilli, E., Sozio, F., Antenucci, F., Aragri, M., Baiocchi, L., Barbaliscia, S., Biliotti, Elisa, Biolato, M., Carioti, L., Ceccherini Silberstein, F., Cerasari, G., Cerva, C., Ciotti, M., D'Ambrosio, C., D'Ettorre, G., De Leonardis, F., De Sanctis, A., Di Maio, V. C., Di Paolo, D., Furlan, Caterina, Gallo, P., Gasbarrini, A., Giannelli, V., Grieco, S., Lambiase, L., Lattanzi, B., Lenci, I., Lula, R., Malagnino, V., Manuelli, M., Miglioresi, L., Milana, M., Moretti, A., Nosotti, L., Palazzo, Donatella, Pellicelli, A., Romano, M., Sarrecchia, C., Sforza, D., Sorbo, M. C., Spaziante, M., Svicher, V., Tisone, G., Vespasiani Gentilucci, U., D'Adamo, G., Mangia, A., Maida, I., Mura, M. S., Falconi, L., Di Giammartino, D., Di Maio, V., Cento, V., Lenci, I., Aragri, M., Rossi, P., Barbaliscia, S., Melis, M., Verucchi, G., Magni, C., Teti, E., Bertoli, A., Antonucci, F., Bellocchi, M., Micheli, V., Masetti, C., Landonio, S., Francioso, S., Santopaolo, F., Pellicelli, A., Calvaruso, V., Gianserra, L., Siciliano, M., Romagnoli, D., Cozzolongo, R., Grieco, A., Vecchiet, J., Morisco, F., Merli, M., Brancaccio, G., Di Biagio, A., Loggi, E., Mastroianni, C., Pace Palitti, V., Tarquini, P., Puoti, M., Taliani, G., Sarmati, L., Picciotto, A., Vullo, V., Caporaso, N., Paoloni, M., Pasquazzi, C., Rizzardini, G., Parruti, G., Craxã¬, A., Babudieri, S., Andreoni, M., Angelico, M., Perno, C., Ceccherini-Silberstein, F., Mariani, R., Iapadre, N., Grimaldi, A., Andreone, P., Menzaghi, B., Quirino, T., Pisani, V., Torti, C., Bruzzone, B., De Maria, A., Marenco, S., Nicolini, L., Viscoli, C., Casinelli, K., Delle Monache, M., Lichtner, M., Aghemo, A., Boccaccio, V., Bruno, S., Cerrone, M., Colombo, M., D'Arminio Monforte, A., Danieli, E., Donato, F., Gubertini, G., Lleo, A., Mancon, A., Monico, S., Niero, F., Russo, M., Gnocchi, M., Orro, A., Milanesi, L., Baldelli, E., Bertolotti, M., Borghi, V., Mussini, C., Gaeta, G., Lembo, V., Sangiovanni, V., DI MARCO, V., Mazzola, A., Petta, S., D'Amico, E., Cacciatore, P., Consorte, A., Pieri, A., Polilli, E., Sozio, F., Antenucci, F., Baiocchi, L., Biliotti, E., Biolato, M., Carioti, L., Cerasari, G., Cerva, C., Ciotti, M., D'Ambrosio, C., D'Ettorre, G., De Leonardis, F., De Sanctis, A., Di Paolo, D., Furlan, C., Gallo, P., Gasbarrini, A., Giannelli, V., Grieco, S., Lambiase, L., Lattanzi, B., Lula, R., Malagnino, V., Manuelli, M., Miglioresi, L., Milana, M., Moretti, A., Nosotti, L., Palazzo, D., Romano, M., Sarrecchia, C., Sforza, D., Sorbo, M., Spaziante, M., Svicher, V., Tisone, G., Vespasiani-Gentilucci, U., D'Adamo, G., Mangia, A., Maida, I., Mura, M., Falconi, L., Di Giammartino, D., Di Maio, V, Cento, V, Lenci, I, Aragri, M, Rossi, P, Barbaliscia, S, Melis, M, Verucchi, G, Magni, C, Teti, E, Bertoli, A, Antonucci, F, Bellocchi, M, Micheli, V, Masetti, C, Landonio, S, Francioso, S, Santopaolo, F, Pellicelli, A, Calvaruso, V, Gianserra, L, Siciliano, M, Romagnoli, D, Cozzolongo, R, Grieco, A, Morisco, F, Merli, M, Brancaccio, G, Di Biagio, A, Loggi, E, Mastroianni, C, Pace Palitti, V, Tarquini, P, Puoti, M, Taliani, G, Sarmati, L, Picciotto, A, Vullo, V, Caporaso, N, Paoloni, M, Pasquazzi, C, Rizzardini, G, Parruti, G, Craxì, A, Babudieri, S, Andreoni, M, Angelico, M, Perno, C, Ceccherini-Silberstein, F, Velia C. Di Maio, Valeria Cento, Ilaria Lenci, Marianna Aragri, Piera Rossi, Silvia Barbaliscia, Michela Meli, Gabriella Verucchi, Carlo F. Magni, Elisabetta Teti, Ada Bertoli, Francesco Paolo Antonucci, Maria C. Bellocchi, Valeria Micheli, Chiara Masetti, Simona Landonio, Simona Francioso, Francesco Santopaolo, Adriano M. Pellicelli, Vincenza Calvaruso, Laura Gianserra, Massimo Siciliano, Dante Romagnoli, Raffaele Cozzolongo, Antonio Grieco, Jacopo Vecchiet, Filomena Morisco, Manuela Merli, Giuseppina Brancaccio, Antonio Di Biagio, Elisabetta Loggi, Claudio M. Mastroianni, Valeria Pace Palitti, Pierluigi Tarquini, Massimo Puoti, Gloria Taliani, Loredana Sarmati, Antonino Picciotto, Vincenzo Vullo, Nicola Caporaso, Maurizio Paoloni, Caterina Pasquazzi, Giuliano Rizzardini, Giustino Parruti, Antonio Craxì, Sergio Babudieri, Massimo Andreoni, Mario Angelico, Carlo F. Perno, Francesca Ceccherini-Silberstein, for the HCV Italian Resistance Network Study Group: [.., P. Andreone, E. Loggi, G. Verucchi, ], Di Maio, Velia C., Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F., Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C., Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M., Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio M., Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxã¬, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F., Ceccherini-Silberstein, Francesca, Nicolini, L. A., Magni, C. F., Russo, M. L., Gaeta, G. B., Di Marco, V., Di Maio, V. C., Sorbo, M. C., Mura, M. S., Di Maio, Velia C, Magni, Carlo F, Bellocchi, Maria C, Pellicelli, Adriano M, Mastroianni, Claudio M, Craxì, Antonio, Perno, Carlo F, and Ceccherini Silberstein, Francesca

Subjects
Male, 0301 basic medicine, hepatitis C virus, Sustained Virologic Response, Sofosbuvir, Hepacivirus, Drug Resistance, resistance-associated substitutions, Viral Nonstructural Proteins, VARIANTS, NS5A, medicine.disease_cause, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Recurrence, INFECTION, antiviral therapy, Medicine, hepatitis C viru, Viral, Treatment Failure, Chronic, direct-acting antivirals, resistance test, hepatology, biology, GENOTYPE 1, virus diseases, Middle Aged, Settore MED/07 - Microbiologia e Microbiologia Clinica, Hepatitis C, Italy, Combination, Interferon, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Author Keywords:antiviral therapy, RIBAVIRIN, Sequence Analysis, Human, medicine.drug, medicine.medical_specialty, Daclatasvir, Genotype, Hepatitis C virus, Antiviral Agents, LONG-TERM PERSISTENCE, DACLATASVIR, 03 medical and health sciences, Drug Therapy, Aged, Drug Resistance, Viral, Hepatitis C, Chronic, Humans, Interferons, Mutation, Ribavirin, Sequence Analysis, DNA, Hepatology, TREATMENT-NAIVE, Internal medicine, Antiviral Agent, resistance-associated substitution, direct-acting antiviral, Hepaciviru, resistance test KeyWords Plus:HEPATITIS-C VIRUS, business.industry, Viral Nonstructural Protein, DNA, biology.organism_classification, Clinical trial, 030104 developmental biology, SOFOSBUVIR, chemistry, Sequence Analysi, Immunology, business
Abstract

Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N= 200) and whenever possible at baseline (N= 70). Results: The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P= 2 DAA classes showed multiclass resistance, including 11/11 NS3+NS5A failures. Furthermore, 20.0% of patients had baseline-RASs, which were always confirmed at failure. Conclusions: In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HCV resistance testing at failure, in all three genes for the best second-line therapeutic tailoring.

Published
2017
Full Text
View/download PDF

20. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Author

Pellicelli Adriano M, Romano Mario, Stroffolini Tommaso, Mazzoni Ettore, Mecenate Fabrizio, Monarca Roberto, Picardi Antonio, Bonaventura Maria, Mastropietro Cristina, Vignally Pascal, Andreoli Arnaldo, Marignani Massimo, D’Ambrosio Cecilia, Miglioresi Lucia, Nosotti Lorenzo, Mitidieri Olga, Gentilucci Umberto, Puoti Claudio, Barbaro Giuseppe, Barlattani Angelo, Furlan Caterina, and Barbarini Giorgio

Subjects
Genotype 1a, HCV genotype 1 subtypes, Sustained virological response, Antiviral therapy, Pegylated interferon, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background The impact of viral subtype on the rate of sustained virological response (SVR) to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated. The aim of this study is to determine whether the HCV genotype 1 subtypes 1a and 1b respond differently to treatment with PEGylated interferon (PEG-IFN) plus ribavirin. Methods For 48 weeks, 388 “naïve”genotype 1 patients were treated weekly with PEG-IFN α-2a or PEG-INF α-2b combined with daily ribavirin (1000–1200 mg/day). The numbers of patients in whom HCV-RNA was undetectable were compared after 4 (rapid virological response, RVR), 12 (early virological response, EVR), and 48 (end treatment virological response, ETR) weeks of treatment as well as 24 weeks after the last treatment (sustained virological response, SVR). Results The rate of SVR was higher in subtype 1a patients than subtype 1b patients (55% vs. 43%; p 10 IU/ml (OR: 3.2; 95% CI: 2.7 to 6.9) and fibrosis score < S3 (OR: 3.8; 95% CI:3.2 to 7.4), were all independent predictors of SVR. Conclusion Dual antiviral therapy is more effective against HCV subtype 1a than against subtype 1b and this difference is independent of other factors that may favour viral clearance. Trial registration ClinicalTrials.gov Identifier: NCT01342003

Published
2012
Full Text
View/download PDF

21. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

Author

Picardi Antonio, Arcuri Pasquale, Nosotti Lorenzo, Bonaventura Maria, Mazzoni Ettore, Barlattani Angelo, Romano Mario, Barbaro Giuseppe, Pellicelli Adriano M, Mecenate Fabrizio, Barbarini Giorgio, D'Ambrosio Cecilia, Paffetti Amerigo, Andreoli Arnaldo, and Soccorsi Fabrizio

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background In patients with chronic hepatitis C virus (HCV) genotype 2 or 3, 24 weeks' treatment with pegylated interferon alfa (PEG-IFN-alpha) and ribavirin induces a sustained virological response (SVR) in almost 80% of cases. Evidence suggests that a similar response rate may be obtained with shorter treatment periods, especially in patients with a rapid virological response (RVR). The aim of this study was to compare the efficacy of 12 or 24 weeks of treatment in patients with chronic HCV genotype 2 or 3 and to identify patients suitable for 12 weeks treatment. Methods Two hundred and ten patients received PEG-IFN-alpha-2a (180 ug/week) and ribavirin (800-1200 mg/day) for 4 weeks. Patients with a RVR (HCV RNA not detectable) were randomized (1:1) to either 12 (group A1) or 24 (group A2) weeks of combination therapy. Patients without a RVR continued with 24-weeks' combination therapy (group B). HCV RNA was monitored at weeks 4, 8, 12, and 24, and at week 24 post-treatment. Results At study end, end of treatment response (ETR) was observed in 62 (86%) patients of group A1 and in 55 (77%) patients of group A2 (p < 0.05) Relapse rate was 3% each in groups A1 and A2, and 6% in group B. Among patients with a HCVRNA test 24 weeks after the end of treatment, SVR was observed in 60 (83%) of group A1 patients and in 53 (75%) of group A2 patients. Rapid virological response, low baseline HCV RNA levels, elevated alanine aminotransferase levels and low fibrosis score, were the strongest covariates associated with SVR, independent of HCV genotype. No baseline characteristic was associated with relapse. Conclusion In HCV patients with genotype 2 or 3, 12-week combination therapy is as efficacious as 24-week therapy and several independent covariates were predictive of SVR. Trial registration Trial number ISRCTN29259563

Published
2010
Full Text
View/download PDF

23. Eustachian valve endocarditis: a rare localization of right side endocarditis. A case report and review of the literature

Author

Terranova Antonio, Pino Paolo, Pellicelli Adriano M, D'Ambrosio Cecilia, and Soccorsi Fabrizio

Subjects
Eustachian valve endocarditis, transthoracic echocardiography, intravenous drug abuse, staphylococcus aureus, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background Right-sided endocarditis occurs predominantly in intravenous drug users, in patients with pacemaker or central venous lines and in patients with congenital heart disease. The vast majority of cases involve the tricuspid valve. Eustachian valve endocarditis is an uncommon disease with similar signs and symptoms of the tricuspid valve endocarditis. A series of only 16 cases of eustachian valve endocarditis are reported in the literature. Case Presentation We present a case of a 25-year old woman with intravenous drug abuse who had a staphylococcus aureus tricuspid valve endocarditis associated to eustachian valve endocarditis. Transthoracic echocardiography, as first line examination, showed the vegetations on tricuspid and eustachian valve. Conclusion Our case describe an unusual location of right side endocarditis in a intravenous drug abuser. In our case, in accord with other cases described in the literature, transthoracic echocardiography disclosed eustachian valve endocarditis. Antimicrobial management is not altered by the recognition of eustachian valve endocarditis. Antibiotic treatment and duration of eustachian endocarditis depends on the isolated organism and is similar to antibiotic therapy used in native valve endocarditis.

Published
2005
Full Text
View/download PDF

24. Lack of reduction in serum alpha‐fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus‐related cirrhosis

Author

Masetti, Chiara, primary, Lionetti, Raffaella, additional, Lupo, Marinella, additional, Siciliano, Massimo, additional, Giannelli, Valerio, additional, Ponziani, Francesca Romana, additional, Teti, Elisabetta, additional, Dell'Unto, Chiara, additional, Francioso, Simona, additional, Brega, Arianna, additional, Montalbano, Marzia, additional, Visco‐Comandini, Ubaldo, additional, Taibi, Chiara, additional, Galati, Giovanni, additional, Vespasiani Gentilucci, Umberto, additional, Picardi, Antonio, additional, Andreoni, Massimo, additional, Pompili, Maurizio, additional, Pellicelli, Adriano M., additional, D'Offizi, Gianpiero, additional, Gasbarrini, Antonio, additional, De Santis, Adriano, additional, and Angelico, Mario, additional

Published
2018
Full Text
View/download PDF

25. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment

Author

Antonelli, Giulio, primary, Gigante, Elia, additional, Iavarone, Massimo, additional, Begini, Paola, additional, Sangiovanni, Angelo, additional, Iannicelli, Elsa, additional, Biondetti, Piero, additional, Pellicelli, Adriano M., additional, Miglioresi, Lucia, additional, Marchetti, Paolo, additional, Lampertico, Pietro, additional, and Marignani, Massimo, additional

Published
2018
Full Text
View/download PDF

26. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis

Author

Masetti, Chiara, Lionetti, Raffaella, Lupo, Marinella, Siciliano, Massimo, Giannelli, Valerio, Ponziani, Francesca Romana, Teti, Elisabetta, Dell'Unto, Chiara, Francioso, Simona, Brega, Arianna, Montalbano, Marzia, Visco-Comandini, Ubaldo, Taibi, Chiara, Galati, Giovanni, Vespasiani Gentilucci, Umberto, Picardi, Antonio, Andreoni, Massimo, Pompili, Maurizio, Pellicelli, Adriano M., D'Offizi, Gianpiero, Gasbarrini, Antonio, De Santis, Adriano, Angelico, Mario, Ponziani, Francesca Romana (ORCID:0000-0002-5924-6238), Pompili, Maurizio (ORCID:0000-0001-6699-7980), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Masetti, Chiara, Lionetti, Raffaella, Lupo, Marinella, Siciliano, Massimo, Giannelli, Valerio, Ponziani, Francesca Romana, Teti, Elisabetta, Dell'Unto, Chiara, Francioso, Simona, Brega, Arianna, Montalbano, Marzia, Visco-Comandini, Ubaldo, Taibi, Chiara, Galati, Giovanni, Vespasiani Gentilucci, Umberto, Picardi, Antonio, Andreoni, Massimo, Pompili, Maurizio, Pellicelli, Adriano M., D'Offizi, Gianpiero, Gasbarrini, Antonio, De Santis, Adriano, Angelico, Mario, Ponziani, Francesca Romana (ORCID:0000-0002-5924-6238), Pompili, Maurizio (ORCID:0000-0001-6699-7980), and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

Risk of hepatocellular carcinoma (HCC) in hepatitis C virus cirrhotic patients treated with direct-acting antiviral agents (DAA) is still debating. We investigated it in a large cohort. The cohort comprised 1045 cirrhotic patients who completed treatment with DAA, with a median follow-up of 17.3 months after end of treatment (EOT), including 943 patients without history of HCC and 102 previously treated for HCC. The majority were men (59.9%), with compensated cirrhosis (88.8%), genotype 1b (44.7%). Univariate, multivariate analysis and Kaplan-Meier curves were performed to detect predictors of HCC in patients with and without reduction in alpha-fetoprotein (AFP) during treatment. SVR12 was 95.6%. HCC developed in 95 (9.9%), including 54 of 943 (5.7%) occurrent and 41 of 102 (39%) recurrent tumours. De novo were more often unifocal (P = 0.01) and curable (P = 0.03). AFP decreased from 16.1 ± 36.2 mg/dL (baseline) to 11.4 ± 55 mg/dL (EOT). At univariate analysis, predictors were a previous HCC, older age, higher model for end-stage liver disease, prolonged INR, lower platelets, baseline and EOT AFP, virological failure and no reduction in AFP during treatment. Kaplan-Meier curves showed lower incidence of HCC in patients showing any reduction in AFP (P = 0.001). Those with AFP <6 ng/mL had the lowest risk (P = 0.0002). At logistic regression, platelets (P = 0.009, OR 0.99 CI: 0.99-1.00), previous HCC (P < 0.000 01, OR: 10.76, 95% CI: 5.89-19.34) and no reduction in AFP during treatment (P = 0.0005, OR: 2.98, CI: 1.60-5.54) were independent predictors of HCC. In conclusion, risk of HCC after DAA treatment remains substantial. It is higher among patients with previous HCC, low platelets and without reduction in AFP during treatment.

Published
2018

27. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

Author

Di Maio, Velia C, Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F, Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C, Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M, Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio M, Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxì, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F, Ceccherini-Silberstein, Francesca, Grieco, Antonio (ORCID:0000-0002-0544-8993), Di Maio, Velia C, Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F, Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C, Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M, Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio M, Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxì, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F, Ceccherini-Silberstein, Francesca, and Grieco, Antonio (ORCID:0000-0002-0544-8993)

Abstract

BACKGROUND & AIMS: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. METHODS: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N=200) and whenever possible at baseline (N=70). RESULTS: The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P<.001). Interestingly, 57.1% of DAA IFN-free non-responders had a misclassified genotype, and 3/4 sofosbuvir breakthroughs showed the major-RAS-S282T, while RAS-L159F was frequently found in sofosbuvir relapsers (18.2%). Notably, 9.0% of patients showed also extra target RASs, and 47.4% of patients treated with ≥2 DAA classes showed multiclass resistance, including 11/11 NS3+NS5A failures. Furthermore, 20.0% of patients had baseline-RASs, which were always confirmed at failure. CONCLUSIONS: In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HCV resis

Published
2017

28. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation

Author

Ettorre, Giuseppe Maria, primary, Levi Sandri, Giovanni Battista, additional, Laurenzi, Andrea, additional, Colasanti, Marco, additional, Meniconi, Roberto Luca, additional, Lionetti, Raffaella, additional, Santoro, Roberto, additional, Lepiane, Pasquale, additional, Sciuto, Rosa, additional, Pizzi, Giuseppe, additional, Cianni, Roberto, additional, Golfieri, Rita, additional, D’Offizi, Gianpiero, additional, Pellicelli, Adriano M., additional, Antonini, Mario, additional, and Vennarecci, Giovanni, additional

Published
2016
Full Text
View/download PDF

30. Liver cirrhosis and rhino-orbital mucormycosis, a possible but rare association: description of a clinical case and literature review

Author

Pellicelli,Adriano M, D'Ambrosio,Cecilia, Villani,Roberto, Cerasari,Giuseppe, Ialongo,Pasquale, Cortese,Andrea, Grillo,Lucia Rosalba, and Soccorsi,Fabrizio

Subjects
rhino-orbital mucormycosis, mucor, genetic structures, surgical treatment, Liver cirrhosis, immunocompromised patients, otorhinolaryngologic diseases, sense organs, eye diseases
Abstract

Only few cases of rhino-orbital mucormycosis in patients with liver cirrhosis are described in the literature and most of these patients showed an associated diabetes mellitus. We describe a case of rhino-orbital mucormycosis in a patient with liver cirrhosis without other risk factors.

Published
2009

31. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.

Author

Pellicelli, Adriano M., Pace Palitti, Valeria, Vignally, Pascal, Ceccherini ‐ Silberstein, Francesca, Siciliano, Massimo, Giannelli, Valerio, Moretti, Alessandra, Tarquini, Pierluigi, Scifo, Gaetano, Messina, Vincenzo, Ascione, Antonio, Izzi, Antonio, Marignani, Massimo, D'Ambrosio, Cecilia, Fondacaro, Lucia, Ettorre, Giuseppe M., Ialongo, Pasquale, Sacco, Rodolfo, Perno, Carlo F., and Barbarini, Giorgio

Subjects
*RIBAVIRIN, *ANTIVIRAL agents, *HEPATITIS C treatment, *HEPATITIS C virus, *TREATMENT of cirrhosis of the liver, SOFOSBUVIR
Abstract

Background & Aims The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir ( SOF) and simeprevir ( SMV) plus a flat dose of 800 mg/d ribavirin ( RBV) in elderly patients with cirrhosis compared to younger patients. Methods Retrospective observational multicentre real-life investigation study of SOF/ SMV/ RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. Results Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were ≥65 years of age. Sustained virological response at 12 weeks ( SVR12) was achieved by 94.2% (129/137) of those aged <65 years and 97.7% (130/133) of those ≥65 years. Diabetes was the most common comorbidity in patients ≥65 years compared to younger patients (26.3% vs 12.4% P<.003). The most common adverse event ( AE) in elderly patients was a grade 2 anaemia (35.3% vs 19.9% P<.004). Conclusions Sofosbuvir/simeprevir plus a daily flat dose of RBV 800 mg for 12 weeks was highly effective and safe in genotype 1 elderly patients with compensated cirrhosis. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

32. Reply

Author

Pellicelli, Adriano M., primary and Angelico, Mario, additional

Published
2015
Full Text
View/download PDF

33. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma

Author

Pellicelli, Adriano M., primary, Vignally, Pascal, additional, Messina, Vincenzo, additional, Izzi, Antonio, additional, Mazzoni, Ettore, additional, Barlattani, Angelo, additional, Bacca, Donato, additional, Romano, Mario, additional, Mecenate, Fabrizio, additional, Stroffolini, Tommaso, additional, Furlan, Caterina, additional, Picardi, Antonio, additional, Gentilucci, Umberto V., additional, Gulminetti, Roberto, additional, Bonaventura, Maria E., additional, Villani, Roberto, additional, D’Ambrosio, Cecilia, additional, Paffetti, Amerigo, additional, Mastropietro, Cristina, additional, Marignani, Massimo, additional, Fondacaro, Lucia, additional, Cerasari, Giuseppe, additional, Andreoli, Arnaldo, additional, and Barbarini, Giorgio, additional

Published
2014
Full Text
View/download PDF

34. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: A retrospective, multicenter, nonrandomized, open-label study

Author

Pellicelli, Adriano M., Barbaro, Giuseppe, Francavilla, Ruggiero, Romano, Mario, Barbarini, Giorgio, Mazzoni, Ettore, Mecenate, Fabrizio, Paffetti, Amerigo, Barlattani, Angelo, Struglia, Carlo, Villani, Roberto, Nauri, Leone, Nosotti, Lorenzo, Armignacco, Orlando, Ferri, Fabrizio, Camporiondo, Maria Pia, and Soccorsi, Fabrizio

Published
2008
Full Text
View/download PDF

45. HIV-related pulmonary hypertension

Author

PELLICELLI, Adriano M., primary, D'AMBROSIO, Cecilia, additional, VIZZA, Carmine Dario, additional, BORGIA, Maria Clotilde, additional, TANZI, Piero, additional, PINO, Paolo, additional, ZACHARA, Elisabeth, additional, and SOCCORSI, Fabrizio, additional

Published
2004
Full Text
View/download PDF

48. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.

Author

Mecenate, Fabrizio, Pellicelli, Adriano M., Barbaro, Giuseppe, Romano, Mario, Barlattani, Angelo, Mazzoni, Ettore, Bonaventura, Maria Elena, Nosotti, Lorenzo, Arcuri, Pasquale, Picardi, Antonio, Barbarini, Giorgio, D'Ambrosio, Cecilia, Paffetti, Amerigo, Andreoli, Arnaldo, and Soccorsi, Fabrizio

Abstract

Background: In patients with chronic hepatitis C virus (HCV) genotype 2 or 3, 24 weeks' treatment with pegylated interferon alfa (PEG-IFN-alpha) and ribavirin induces a sustained virological response (SVR) in almost 80% of cases. Evidence suggests that a similar response rate may be obtained with shorter treatment periods, especially in patients with a rapid virological response (RVR). The aim of this study was to compare the efficacy of 12 or 24 weeks of treatment in patients with chronic HCV genotype 2 or 3 and to identify patients suitable for 12 weeks treatment. Methods: Two hundred and ten patients received PEG-IFN-alpha-2a (180 ug/week) and ribavirin (800-1200 mg/day) for 4 weeks. Patients with a RVR (HCV RNA not detectable) were randomized (1:1) to either 12 (group A1) or 24 (group A2) weeks of combination therapy. Patients without a RVR continued with 24-weeks' combination therapy (group B). HCV RNA was monitored at weeks 4, 8, 12, and 24, and at week 24 post-treatment. Results: At study end, end of treatment response (ETR) was observed in 62 (86%) patients of group A1 and in 55 (77%) patients of group A2 (p < 0.05) Relapse rate was 3% each in groups A1 and A2, and 6% in group B. Among patients with a HCVRNA test 24 weeks after the end of treatment, SVR was observed in 60 (83%) of group A1 patients and in 53 (75%) of group A2 patients. Rapid virological response, low baseline HCV RNA levels, elevated alanine aminotransferase levels and low fibrosis score, were the strongest covariates associated with SVR, independent of HCV genotype. No baseline characteristic was associated with relapse. Conclusion: In HCV patients with genotype 2 or 3, 12-week combination therapy is as efficacious as 24-week therapy and several independent covariates were predictive of SVR. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

49. Endocarditis Caused by Aspergillus Species in Injection Drug Users.

Author

Petrosillo, Nicola, Pellicelli, Adriano M., Cicalini, Stefania, Conte, Aristide, Goletti, Delia, and Palmieri, Fabrizio

Subjects
*ENDOCARDITIS, *ASPERGILLUS, *ASPERGILLOSIS, *MYCOSES, *PEOPLE with drug addiction, *DISEASES
Abstract

Describes cases of Aspergillus endocarditis in injection drug users (IDU). Risk factors associated with the acquisition of invasive aspergillosis; Percentage of infections in IDU attributed to fungal infections; Association of Aspergillus endocarditis with HIV infection.

Published
2001
Full Text
View/download PDF

50. Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies

Author

Di Maio, Velia Chiara, Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Barbaliscia, Silvia, Francioso, Simona, Stefania Paolucci, Melis, Michela, Verucchi, Gabriella, Coppola, Nicola, Magni, Carlo F., Santopaolo, Francesco, Landonio, Simona, Ghisetti, Valeria, Starace, Mario, D Ambrosio, Cecilia, Calvaruso, Vincenzo, Caporasol, Nicola, Pasquazzi, Caterina, Maida, Ivana, Picciotto, Antonino, Di Biagio, Antonio, Sticchi, Laura, Cozzolongo, Raffaele, Romagnoli, Dante, Biolato, Marco, Vecchiet, Jacopo, D Ettorre, Gabriella, Merli, Manuela, Gaeta, Giovanni B., Ciancio, Alessia, Marinaro, Letizia, Andreone, Pietro, Barbarini, Giorgio, Gulminetti, Roberto, Palitti, Valeria Pace, Tarquini, Perluigi, Puoti, Massimo, Sangiovanni, Vincenzo, Paoloni, Maurizio, Babudieri, Sergio, Rizzardini, Giuliano, Bruno, Savino, Andreoni, Massimo, Pellicelli, Adriano M., Parruti, Giustino, Craxi, Antonio, Angelico, Mario, Perno, Carlo F., and Ceccherini-Silberstein, Francesca

Catalog

Books, media, physical & digital resources
See catalog results